RxDoctor Payments Data

Amanda Moore Miller, MD

Internal Medicine · Knoxville, TNNPI 1952514028

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 4 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 3 manufacturers reported payments, led by AbbVie at 44.5% of the total. That places this record below the midpoint for internal medicine clinicians in TN, where the typical reported total is $226.

$72in general payments, 2019–2025

Across 4 payments — averaging $18.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$32
  • Eagle Pharmaceuticals, Inc.$21
  • Portola Pharmaceuticals, LLC$19
$2,344,836in research payments, 2019–2025

Across 22 payments — averaging $106,583 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$2.3M
  • Alnylam Pharmaceuticals Inc.$57K
  • Pfizer$17K

What the payments were for

  • Food & beverage$72100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$72 in reported general payments places this provider in the 30th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$2,175
Medicare patients
26
Services billed
30

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Valsartan24$504

Paid to pharmacies, not to this prescriber.

Other internal medicine in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →